Condition
Non-Small Cell Adenocarcinoma
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 1 (2)
P 2 (1)
Trial Status
Unknown2
Completed1
Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06810544Phase 1Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT04985604Phase 2Terminated
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
NCT06517485Phase 1Completed
First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b
NCT06207292Not ApplicableUnknown
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer
NCT03071705Not ApplicableUnknownPrimary
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma
Showing all 5 trials